FindTrial
Sign In

Fluticasone Furoate/Vilanterol

DRUG9 trials

Sponsors

GlaxoSmithKline

Conditions

AsthmaPulmonary Disease, Chronic Obstructive

Phase 1

Relovair PD PK in Chinese Healthy Subjects
CompletedNCT01711463
GlaxoSmithKlineAsthma
Start: 2012-12-05End: 2013-06-04Updated: 2017-07-25

Phase 2

Inhaled Fluticasone Furoate/Vilanterol Safety and Tolerability, PK and PD Study
CompletedNCT01453023
GlaxoSmithKlineAsthma
Start: 2011-10-31End: 2012-06-30Updated: 2017-01-11

Phase 3

Study to Evaluate the Effect of Fluticasone Furoate/Vilanterol on Survival in Subjects With Chronic Obstructive Pulmonary Disease
CompletedNCT01313676
GlaxoSmithKlinePulmonary Disease, Chronic Obstructive
Start: 2011-01-25End: 2015-07-15Updated: 2018-08-06
A 24-week Arterial Stiffness Study With Fluticasone Furoate/Vilanterol in COPD
CompletedNCT01336608
GlaxoSmithKlinePulmonary Disease, Chronic Obstructive
Start: 2011-03-04End: 2014-11-04Updated: 2017-11-08
A 24-week Study of Fluticasone Furoate/Vilanterol Inhalation Powder in Subjects of Asian Ancestry With COPD
CompletedNCT01376245
GlaxoSmithKlinePulmonary Disease, Chronic Obstructive
Start: 2011-04-30End: 2012-09-30Updated: 2017-01-11
A Study to Compare the Efficacy and Safety of Fluticasone Furoate (FF) 100 mcg Once Daily With Fluticasone Propionate (FP) 250 mcg Twice Daily (BD) and FP 100 mcg BD in Well-controlled Asthmatic Japanese Subjects
CompletedNCT02094937
GlaxoSmithKlineAsthma
Start: 2014-03-27End: 2015-08-28Updated: 2017-05-25
Study Evaluating the Efficacy and Safety of Fluticasone Furoate/Vilanterol Inhalation Powder (FF/VI) Compared With Vilanterol Inhalation Powder (VI) in Subjects With Chronic Obstructive Pulmonary Disease (COPD)
CompletedNCT02105974
GlaxoSmithKlinePulmonary Disease, Chronic Obstructive
Start: 2014-04-07End: 2015-07-08Updated: 2018-01-24

Phase 4

Study Evaluating the Effect of Fluticasone Furoate/ Vilanterol (FF/VI) Inhalation Powder Compared With Vilanterol (VI) Inhalation Powder on Bone Mineral Density (BMD) in Subjects With Chronic Obstructive Pulmonary Disease (COPD).
CompletedNCT01957150
GlaxoSmithKlinePulmonary Disease, Chronic Obstructive
Start: 2014-01-28End: 2018-03-26Updated: 2019-04-10
The Efficacy of Fluticasone Furoate/Vilanterol Versus (vs) Fluticasone Furoate on Asthma
WithdrawnNCT03363191
GlaxoSmithKlineAsthma
Start: 2018-03-07End: 2019-05-29Updated: 2018-01-29

Related Papers

Estimating individual treatment effects on COPD exacerbations by causal machine learning on randomised controlled trials
Thorax2023-04-0317 citations
Pragmatic randomised controlled trials in COPD and asthma: how to guide clinical practice
BMJ Open Respiratory Research2022-09-013 citations
Scores of Health-Related Quality of Life Questionnaire Worsen Consistently in Patients of COPD: Estimating Disease Progression over 30 Years by SReFT with Individual Data Collected in SUMMIT Trial
Journal of Clinical Medicine2020-08-185 citations
<p>The Summit Score Stratifies Mortality and Morbidity in Chronic Obstructive Pulmonary Disease</p>
International Journal of COPD2020-07-013 citations
Single-inhaler triple therapy fluticasone furoate/umeclidinium/vilanterol versus fluticasone furoate/vilanterol and umeclidinium/vilanterol in patients with COPD: results on cardiovascular safety from the IMPACT trial.
2020-06-0510 citations
Association of platelet count with all-cause mortality and risk of cardiovascular and respiratory morbidity in stable COPD
Respiratory Research2019-05-0835 citations
Serum biomarkers and outcomes in patients with moderate COPD: a substudy of the randomised SUMMIT trial
BMJ Open Respiratory Research2019-05-0153 citations
Impact of pre-enrolment medication use on clinical outcomes in SUMMIT
ERJ Open Research2019-02-015 citations
Cardiac Troponin I and Cardiovascular Risk in Patients With Chronic Obstructive Pulmonary Disease.
2018-09-0140 citations
β-Blocker Therapy and Clinical Outcomes in Patients with Moderate Chronic Obstructive Pulmonary Disease and Heightened Cardiovascular Risk. An Observational Substudy of SUMMIT
Annals of the American Thoracic Society2018-02-0626 citations
Serum Levels of Club-Cell Protein 16 (CC-16), Surfactant Protein D (SPD), soluble Receptor of Glycation End-products (sRAGE), Fibrinogen and C-Reactive Protein (CRP) and FEV1 Decline, Exacerbations and Mortality in SUMMIT
2017-09-01
Fluticasone Furoate, Vilanterol, and Lung Function Decline in Patients with Moderate Chronic Obstructive Pulmonary Disease and Heightened Cardiovascular Risk
American Journal of Respiratory and Critical Care Medicine2017-07-2461 citations
Cardiovascular outcomes with an inhaled beta2-agonist/corticosteroid in patients with COPD at high cardiovascular risk
Heart2017-04-1748 citations
A randomised, phase III trial of once-daily fluticasone furoate/vilanterol 100/25 μg versus once-daily vilanterol 25 μg to evaluate the contribution on lung function of fluticasone furoate in the combination in patients with COPD.
2016-12-0217 citations
Pulse wave velocity (PWV) in patients (pts) with moderate COPD and cardiovascular risk: The effect of an inhaled long-acting β<sub>2</sub>-agonist/corticosteroid (SUMMIT)
2016-09-012 citations
Fluticasone furoate and vilanterol and survival in chronic obstructive pulmonary disease with heightened cardiovascular risk (SUMMIT): a double-blind randomised controlled trial.
2016-04-28323 citations
Efficacy and safety of fluticasone furoate/vilanterol (50/25 mcg; 100/25 mcg; 200/25 mcg) in Asian patients with chronic obstructive pulmonary disease: a randomized placebo-controlled trial
Current Medical Research and Opinion2015-04-0151 citations